Helena Salvador Roses

Dr. Helena Salvador Roses

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Maturitas
Verified
Journal Article
Closed access
Elena LoboElena Lobo
Elena Lobo
GMGuillermo Marcos
Guillermo Marcos
JSJavier Santabárbara
Javier Santabárbara
HRHelena Salvador Roses
Helena Salvador Roses
LLLuis Lobo-Escolar
Luis Lobo-Escolar
Elena LoboElena Lobo
Elena Lobo

1 April 2023 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
HRHelena Salvador Roses
Helena Salvador Roses
AEAlfredo Escartín
Alfredo Escartín
PMPablo Muriel
Pablo Muriel
MSMaite Santamaría
Maite Santamaría
MGMarta González
Marta González
JOJorge-Juan Olsina
Jorge-Juan Olsina

11 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JTJaume Tur-Martínez
Jaume Tur-Martínez
JRJoaquín Rodríguez-Santiago
Joaquín Rodríguez-Santiago
JOJavier Osorio
Javier Osorio
MMMònica Miró
Mònica Miró
CYConcepción Yarnoz
Concepción Yarnoz
MPManuel Pera
Manuel Pera
Background: The aim of this study was to evaluate different preoperative immune, inflammatory, and nutritional scores and their best cut-off values as predictors of poorer overall survival (OS) and disease-free survival (DFS) in patients who underwent curative gastric cancer resection. Methods: This was a retrospective observational multicentre study based on data of the Spanish EURECCA Esophagogastric Cancer Registry. Time-dependent Youden index and log-rank test were used to obtain the best cut-offs of 18 preoperative biomarkers for OS and DFS. An adjusted Cox model with variables selected by bootstrapping was used to identify the best preoperative biomarkers, which were also analysed for every TNM stage. Results: High neutrophil-to-lymphocyte ratio (NLR), high monocyte systemic inflammation index (moSII), and low prognostic nutritional index (PNI) were identified as independent predictors of poor outcome: NLR > 5.91 (HR:1.73; 95%CI [1.23–2.43]), moSII >2027.12 (HR:2.26; 95%CI [1.36–3.78]), and PNI >40.31 (HR:0.75; 95%CI [0.58–0.96]) for 5-year OS and NLR > 6.81 (HR:1.75; 95%CI [1.24–2.45]), moSII > 2027.12 (HR:2.46; 95%CI [1.49–4.04]), and PNI > 40.31 (HR:0.77; 95%CI [0.60,0.97]) for 5-year DFS. These outcomes were maintained in the whole cohort for NLR and moSII (p < 0.05) but not in stage II and for PNI in all tumoral stages. The associations of NLR-PNI and moSII-PNI were also a relevant prognostic factor for OS. Conclusions: High NLR, high moSII (for stages I and III), and low PNI (regardless of tumour stage) were the most promising preoperative biomarkers to predict poor OS and DFS in gastric cancer patients treated with curative intent.

22 December 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HRHelena Salvador Roses
Helena Salvador Roses
SLS. López-Ben
S. López-Ben
MCM. Casellas-Robert
M. Casellas-Robert
PPPere Planellas
Pere Planellas
NGN. Gómez-Romeu
N. Gómez-Romeu
JFJ. Figueras
J. Figueras

30 March 2020 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
PPPere Planellas
Pere Planellas
LCLidia Cornejo
Lidia Cornejo
HRHelena Salvador Roses
Helena Salvador Roses
MBMaria Buxo
Maria Buxo
RCRamon Farrés Coll
Ramon Farrés Coll
ACAntoni Codina Cazador
Antoni Codina Cazador

13 July 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HRHelena Salvador Roses
Helena Salvador Roses
SLS. López-Ben
S. López-Ben
PPPere Planellas
Pere Planellas
ECE. Canals
E. Canals
MCM. Casellas-Robert
M. Casellas-Robert
JFJ. Figueras
J. Figueras